BMT CTN Protocol 0301

Fludarabine-based Conditioning for Allogeneic Marrow Transplantation from HLA-compatible Unrelated Donors in Severe Aplastic Anemia

Below are protocol-related documents, which may be periodically updated.

            Protocol Chair:  Paolo Anderlini, MD (713-794-5743)

            Protocol Officer:  Mary Eapen, MD (414-805-0700)

            Protocol Statistician: Adam Mendizabal, PhD (301-251-1161)   

            Protocol Coordinator: Iris Gersten (301-251-1161)

            Medical Monitor: Chris Bredeson, MD


This study reached target accrual and was closed to patient accruals on December 2, 2013.